There were significant differences in weight loss (LC 4.6 0.9 vs
For instance, the addition of ganitumab, a monoclonal antibody targeting IGF-1R, to carboplatin/paclitaxel chemotherapy in patients with primary epithelial ovarian cancer did not improve progression-free survival in a phase II multicenter controlled trial (65), despite the promising results of IGF-1R inhibition in various preclinical studies (25, 32, 64)
Animal studies demonstrate accelerated tendon, ligament, and muscle repair through enhanced angiogenesis and growth factor modulation
Como todos, este medicamento tiene efectos secundarios y riesgos, como nuseas, dolor de estmago, vmitos, diarrea y el llamada "efecto rebote" una vez que se deja de utilizar, lo que provoca que la persona gane el peso perdido o ms